Key result
Aggressive chemotherapy with the CODOX-M/IVAC regimen reduced the size of multiple cardiac masses and stabilized the clinical condition of a 37-year-old male with secondary cardiac lymphoma.
Case Report (n=1)
Multimodality imaging is essential for the diagnosis, staging, and monitoring of secondary cardiac lymphoma, which can respond rapidly to aggressive chemotherapy.
Answers are grounded in this paper and cite their sources.
May support chemotherapy response in secondary cardiac lymphoma; hypothesis-generating and should not yet change practice.
SummaryThirty-seven-year-old male presented with cough, dyspnea, significant weight loss (20 kg) and subacute fever for the past 2 months. Physical examination revealed inspiratory and expiratory wheezing bilaterally. A normal S1, S2 and a 3/6 systolic ejection murmur at the left upper parasternal border with respiratory variation were found during cardiac auscultation. Kidney and bone marrow biopsy reported a high-grade B-cell lymphoma. Echocardiography and cardiac CT findings consisted of multiple intracardiac masses affecting the right ventricular (RV) outflow track, RV apex, medial portion of the right atrium and posterior left atrium, as well as mild impairment of the RV systolic function. The masses in the RV outflow track caused partial obstruction (pulmonary valve peak velocity 2.3 m/s) with a RV systolic pressure of 43 mmHg. The infiltrative mass in the interatrial septum extended into both the right and left atrial cavities. The right superior pulmonary vein was occluded. This patient was treated with aggressive chemotherapy and had a good clinical response that resulted in mass size reduction after the first course of chemotherapy. Multimodality imaging techniques such as echocardiography, cardiac CT and PET scan can provide complementary information to better evaluate, stage and manage these patients. LEARNING POINTS: Lymphoma can be found as a primary tumor in cardiac tissue, but secondary cardiac lymphoma is far more common.Appropriate investigation, histopathology, immunophenotype, staging and risk assessment are required for definite diagnosis and treatment.Cardiac lymphoma frequently manifests as an ill-defined, infiltrative mass. Typical location is in the atrium (right atrium is the most common site). Pericardial thickening or effusion is also common.Echocardiography is a quick, bedside, non-invasive assessment of anatomical involvement and hemodynamics affected by cardiac lymphoma. Echocardiographic findings of cardiac lymphoma include a hypoechoic, ill-defined infiltrative masses in the myocardium, nodular protrusion into cardiac chambers and pericardial effusion. Obstruction of inflow/outflow track can also be found.If a diagnosis of cardiac lymphoma is made, the most effective treatment is chemotherapy. Surgical treatment may have a role when hemodynamic compromise does not respond to chemotherapy and radiotherapy.
No takes yet. Share an insight, caveat, or question.
Indrabhinduwat et al. (2018) conducted a case report in Secondary cardiac lymphoma (n=1). Chemotherapy (CODOX-M/IVAC regimen) was evaluated on Tumor size and clinical response. Aggressive chemotherapy with the CODOX-M/IVAC regimen reduced the size of multiple cardiac masses and stabilized the clinical condition of a 37-year-old male with secondary cardiac lymphoma.
Synapse has enriched 10 related papers. Consider them for comparative context: